Short interest for Chimerix gives investors a sense of the degree to which investors are betting on the decline of Chimerix's stock. Short interest data is updated every two weeks.

Chimerix Stock (NASDAQ:CMRX), Short Interest Report

Chimerix

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ALZN

CMRX

NTWK

The Dow Jones closed lower by around 388 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying

Small Cap

AMBA

CGEN

COHU

CWAN

EIGR

GBIO

IGMS

IRTC

ITOS

JNPR

KYMR

LABP

LIFE

MIRM

NOVT

ONCR

PAYO

PRAX

RKLB

ROKU

SGMO

SIVB

STIM

STTK

XFOR

The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the company’s Silicon Valley Bank.

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank

Analyst Color

Mid Cap

Topics

Analyst Ratings

Tech

General

Shares of Sunrun Inc (NASDAQ: RUN), the largest residential solar developer in the U.S, fell by as much as 15% on Friday as a result of the news that Silicon Valley Bank has been closed by the 

Sunrun Down Over 10% On Silicon Valley Bank Exposure: What Other Companies Are Exposed?

Chimerix Inc

Dordaviprone is an oral, first-in-class small molecule imipridone that selectively binds to the G-protein coupled dopamine receptor D2 (DRD2) and the mitochondrial protease ClpP.&nbsp;

Guidance

Chimerix Expects Dordaviprone Interim Overall Survival Data In 2025 And Final OS Data In 2026

Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 4.17 percent decrease over losses of $(0.24) per share from the same period last year.

Earnings

Earnings Misses

Chimerix Q1 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate

<a href="https://twitter.com/DrTedros/status/1778423967105139108">https://twitter.com/DrTedros/status/1778423967105139108</a>
&nbsp;
&nbsp;

Biotech

Global

AEMD

GOVX

MRNA

SIGA

TNXP

WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."

HC Wainwright &amp; Co. analyst Edward White reiterates Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) with a Buy and maintains $11 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target

Chimerix Q4 Cash and Equivalents $204M

Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 16.67 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $4.00 thousand which missed the analyst consensus estimate of $60.00 thousand by 93.33 percent. This is a 99.51 percent decrease over sales of $814.00 thousand the same period last year.

Chimerix Q4 EPS $(0.20) Beats $(0.24) Estimate, Sales $4.00K Miss $60.00K Estimate

Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-29. Here's what investors need to know before the announcement.
Analysts estimate that Chimerix will report an earnings per share (EPS) of $-0.24. 
Chimerix bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.04, which was followed by a 8.16% increase in the share price the next day.
Here's a look at Chimerix's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.23</td>
<td>-0.24</td>
<td>-0.25</td>
<td>-0.24</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.27</td>
<td>-0.21</td>
<td>-0.24</td>
<td>-0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.0%</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709146875_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Chimerix were trading at $1.205 as of February 27. Over the last 52-week period, shares are down 25.44%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CMRX/earnings">To track all earnings releases for Chimerix visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Chimerix's Earnings

<a href="https://www.reuters.com/business/healthcare-pharmaceuticals/who-very-worried-about-spread-mpox-drc-2023-12-08/?taid=65734f21df0b0e0001648213&amp;utm_campaign=trueanthem&amp;utm_medium=trueanthem&amp;utm_source=twitter">https://www.reuters.com/business/healthcare-pharmaceuticals/who-very-worried-about-spread-mpox-drc-2023-12-08/?taid=65734f21df0b0e0001648213&amp;utm_campaign=trueanthem&amp;utm_medium=trueanthem&amp;utm_source=twitter</a>
The World Health Organization is "very worried" about the spread of a severe form of mpox that has killed nearly 600 people, mainly children, in the Democratic Republic of Congo this year, a senior official said.
The country has reported over 13,000 cases in 2023, more than twice as many as during the last peak in 2020, with the disease occurring in almost every province. The WHO is working with the authorities on the response and a risk assessment.
On Thursday, the U.S. Centers for Disease Control and Prevention (CDC) <a href="https://www.reuters.com/world/africa/us-cdc-issues-health-alert-subtype-mpox-virus-congo-2023-12-07/">issued an alert</a> about the dangerous clade I mpox outbreak.
"The virus variant is known to be more virulent. If it adapts better to human to human transmission, that presents a risk," Rosamund Lewis, WHO's mpox lead, told Reuters by phone from Kinshasa.
Mpox is a viral infection that spreads through close contact, causing flu-like symptoms and pus-filled lesions. Most cases are mild but it can kill.
Last year, a less severe form – clade II – began to spread globally, largely through sexual contact among men who have sex with men, and the WHO declared a public health emergency.
New evidence that clade I can also spread through sexual contact is concerning, Lewis said. Mpox can also spread to humans from infected animals or among family members within households, she said. Children and people with weak immune systems are more at risk, with illness leading to death in up to 10% of clade I cases.
"We have very little information of who is dying of mpox [in DRC] other than age," said Lewis, adding more data was needed.
The WHO is also worried about an outbreak among sex workers in South Kivu, because of the vulnerability of the population as well as the risk of the infection spreading to neighbouring countries, she said.
The agency is working with the Congo government to resolve <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/stigma-regulatory-barriers-delay-mpox-response-country-that-needs-it-most-2023-12-05/">regulatory</a> hurdles to enable the country to procure or accept donations of mpox vaccines, currently only available in the country in ongoing clinical studies. There is also a mpox antiviral treatment trial underway.
DRC has not requested any treatments, Lewis said. Getting the vaccine is more complex, she added, because only one region of the WHO has a supply agreement in place. Any donations would also need funding for deployment.

Reported Earlier, "WHO 'Very Worried' About Spread Of Mpox In DRC" - Reuters News

Health Care

Management

Chimerix Announced The Promotion Of Michelle Laspaluto, Vice President Of Corporate Financial Planning And Investor Relations, To Chief Financial Officer Effective December 1, 2023

Thomas Riga, COO and CCO at Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>), reported a large acquisition of company stock options on November 16, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001117480/000120919123055611//Archives/edgar/data/1117480/000120919123055611/0001209191-23-055611-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Riga, COO and CCO at Chimerix, a company in the Health Care sector, was just awarded stock options worth 800,000 shares of CMRX. The options give Riga the right to buy the company's stock at $1.0 per share.
Chimerix shares are trading up 3.0% at $1.03 at the time of this writing on Friday morning. Since the current price is $1.03, this makes Riga's 800,000 shares worth $824,000.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001117480">Check Out The Full List Of Chimerix's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COO and CCO at Chimerix Acquires Company Stock Options Worth 800,000 Shares

Chimerix Expects To End 2023 With Over $200M In Cash And Cash Equivalents Which Is Expected To Be Sufficient To Fund Operations Through Final ACTION Study Data Expected In 2026

Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) is set to give its latest quarterly earnings report on Thursday, 2023-11-02. Here's what investors need to know before the announcement.
Analysts estimate that Chimerix will report an earnings per share (EPS) of $-0.23. 
Chimerix bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.03, which was followed by a 5.17% drop in the share price the next day.
Here's a look at Chimerix's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.24</td>
<td>-0.25</td>
<td>-0.24</td>
<td>2.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.24</td>
<td>-0.24</td>
<td>2.75</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.17%</td>
<td>1.75%</td>
<td>-3.55%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1698865296_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Chimerix were trading at $0.9419 as of October 31. Over the last 52-week period, shares are down 46.94%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/CMRX/earnings">To track all earnings releases for Chimerix visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Chimerix

<h3>The Meaning Behind Value Stocks</h3>
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. 
<h2>The following stocks are considered to be notable value stocks in the healthcare sector:</h2>
<ol>
<li>Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) - P/E: 0.51</li>
<li>Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) - P/E: 3.65</li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) - P/E: 7.53</li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) - P/E: 1.63</li>
<li>Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) - P/E: 7.09</li>
</ol>
This quarter, Chimerix experienced an increase in earnings per share, which was $-0.24 in Q1 and is now $-0.21. Most recently, Voyager Therapeutics reported earnings per share at $-0.51, whereas in Q1 earnings per share sat at $2.94. This quarter, Spero Therapeutics experienced an increase in earnings per share, which was $-0.25 in Q1 and is now $-0.23. Acorda Therapeutics's earnings per share for Q2 sits at $-7.55, whereas in Q1, they were at -13.8. Cross Country Healthcare has reported Q2 earnings per share at $0.69, which has decreased by 17.86% compared to Q1, which was 0.84. 
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

ACOR

CCRN

SPRO

VYGR

Overview Of Value Stocks In The Healthcare Sector

Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) has observed the following analyst ratings within the last quarter: 
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the last 3 months, 4 analysts have offered 12-month price targets for Chimerix. The company has an average price target of $8.75 with a high of $11.00 and a low of $6.00. 
Below is a summary of how these 4 analysts rated Chimerix over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1692302415_0.png" alt="price target chart" />
This current average has decreased by 20.45% from the previous average price target of $11.00. 
<a href="https://www.benzinga.com/quote/CMRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Chimerix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h1>How Are Analyst Ratings Determined?</h1>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Have This to Say About Chimerix

Wedbush analyst David Nierengarten reiterates Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) with a Outperform and maintains $6 price target.

Wedbush Reiterates Outperform on Chimerix, Maintains $6 Price Target

Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control 
&nbsp;
ONC201 Treatment Disrupts Key Metabolic and Epigenetic Pathways
DURHAM, N.C., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the publication of data in support of the Company&#39;s first-in-class small molecule imipridone, ONC201, as a treatment for H3 K27M-mutant diffuse midline gliomas (H3K27M-DMG) in the peer-reviewed journal,&nbsp;Cancer Discovery,&nbsp;a journal of the American Association for Cancer Research.
The manuscript titled,&nbsp;&quot;Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways,&quot;&nbsp;reports survival analyses of 71 patients with H3 K27M-DMG treated with ONC201 which demonstrated promising results in a patient population with a poor prognosis and few treatment options. In addition to assessing clinical outcomes, the study corroborated mechanistic findings from laboratory models in samples from treated patients that demonstrated the ability of ONC201 to disrupt metabolic pathways and reverse the epigenetic consequence (H3K27me3-loss) of the H3 K27M mutation.
&quot;The survival analyses published today in&nbsp;Cancer Discovery&nbsp;reported that ONC201 frontline treatment, administered post radiation therapy, demonstrated a statistically significant increase in mOS from diagnosis versus historical controls (21.7 months mOS vs. 12 months mOS, p&lt;0.0001). These data are particularly relevant given that enrollment in the ongoing ACTION study occurs in a similar population. Additionally, these data further elucidate the underlying novel mechanism of action for ONC201 in a patient population which has very limited treatment options,&quot; said Mike Andriole, Chief Executive Officer of Chimerix. &quot;While these results require validation in prospectively designed studies, such as the Phase 3 ACTION study, they nevertheless provide ongoing confidence and rationale for ONC201&#39;s monotherapy treatment effect and offer hope to the patients, families and caregivers facing this challenging and life-threatening cancer.&quot;
&quot;H3K27M-DMG represents one of the most difficult tumors to treat,&quot; said Carl Koschmann, M.D., Associate Professor of Pediatric Neuro-Oncology and Clinical Scientific Director of the Chad Carr Pediatric Brain Tumor Center at Michigan Medicine. &quot;Prior to this study, there have been more than 250 clinical trials that have not been able to improve outcomes. These results are potentially a major crack in the armor.&quot;
The complete publication can be accessed&nbsp;<a href="https://www.globenewswire.com/Tracker?data=wrJ3W4R8nbYPsS8BbGMi6dbEhV4qtqvjxso1G9yoDmnoK-9fO0QG0MnqqYgHuTBBstzLPz0wfbkltsopHx4dZxQERzF-TqUmhNXCRr-oxWcWlUXGDEAr_zbHPOVbTnp_8_lOO8IE4PJhdHE0MBvgrA==" target="_blank">here</a>.&nbsp;&nbsp;
About the Phase 3 ACTION Study
The Phase 3 ACTION trial is actively recruiting patients in 11 countries across North America, Europe, the UK, Israel and Asia. The trial enrolls patients shortly after completion of front-line radiation therapy that is the standard of care. The study is designed to enroll 450 patients randomized 1:1:1 to receive ONC201 at one of two dosing frequencies or placebo. Participants are randomized to receive 625mg of ONC201 once per week (the Phase 2 dosing regimen), 625mg twice per week on two consecutive days or placebo. The dose will be scaled by body weight for patients &lt;52.5kg. OS will be assessed for efficacy at three alpha-allocated timepoints: two interim assessments by the Independent Data Monitoring Committee (IDMC) at 164 events and 246 events, respectively, and a final assessment at 327 events. The final progression-free survival (PFS) analysis will be performed after 286 events, with progression assessed using RANO HGG criteria by blinded independent central review (BICR). Secondary endpoints include corticosteroid response, performance status response, change from baseline in quality of life (QoL) assessments and change from baseline in neurologic function as assessed by the Neurologic Assessment in Neuro-Oncology (NANO) scale. For more information, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=3YBRH431Eda57H-qJ_SO7syLVvEJPHia3MgsPMBLW9LWnzx4G-vyvEcxCkyxBVjsETPH1zV3kQaJnuGKn0mJLV4SlLQNmLxDU77ImyVssvJ2z3EepXwJ0TtS82zx6pMuEoKlXXV2ujp1pnQBEY9jLD3eNQmsJIErT8mDJ4BTV59B7It9Az5GduWyAIWdM-0i" target="_blank">clinicaltrials.gov</a>.

Chimerix Announces Data Highlighting Clinical Efficacy And Molecular Mechanisms Of Response To ONC201 Treatment Of H3 K27M-Mutant Diffuse Midline Gliomas Published In "Cancer Discovery"

Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 12.5 percent. This is a 22.22 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $26.00 thousand which missed the analyst consensus estimate of $230.00 thousand by 88.70 percent. This is a 94.09 percent decrease over sales of $440.00 thousand the same period last year.

CORRECTION: Chimerix Q2 EPS $(0.21) Beats $(0.24) Estimate, Sales $26.00K Miss $230.00K Estimate; Capital Available to Fund Operations Is $233M

<a href="https://economictimes.indiatimes.com/news/india/27-confirmed-monkeypox-cases-reported-in-india-government-to-lok-sabha/articleshow/102208281.cms" title="https://economictimes.indiatimes.com/news/india/27-confirmed-monkeypox-cases-reported-in-india-government-to-lok-sabha/articleshow/102208281.cms">https://economictimes.indiatimes.com/news/india/27-confirmed-monkeypox-cases-reported-in-india-government-to-lok-sabha/articleshow/102208281.cms</a>
Till July 24, a total of 27 confirmed cases of monkeypox disease were reported in the country, including 12 from Kerala and 15 from Delhi, the government informed Parliament on Friday. In a written response to a question in the Lok Sabha, Minister of State for Health S P Singh Baghel said most of the cases were mild and that the treatment for the disease remains largely supportive.
The World Health Organization (WHO) declared an outbreak of monkeypox disease as a Public Health Emergency &nbsp;.. 
&nbsp;
Read more at: 
<a href="https://economictimes.indiatimes.com/news/india/27-confirmed-monkeypox-cases-reported-in-india-government-to-lok-sabha/articleshow/102208281.cms?utm_source=contentofinterest&amp;utm_medium=text&amp;utm_campaign=cppst">https://economictimes.indiatimes.com/news/india/27-confirmed-monkeypox-cases-reported-in-india-government-to-lok-sabha/articleshow/102208281.cms?utm_source=contentofinterest&amp;utm_medium=text&amp;utm_campaign=cppst</a>

Macro Economic Events

Economics

INDA

'27 Confirmed Monkeypox Cases Reported In India: Government To Lok Sabha' - The Economic Times

The latest announcement is out from Chimerix (CMRX). Patrick Machado has announced his resignation from the Board of Directors of Chimerix, Inc., e...

Chimerix Board Changes: Machado Resigns, Kozin Appointed

Notable earnings before Wednesday's open

Chimerix Q1 2024 Earnings Preview

Chimerix GAAP EPS of -$0.25

The latest update is out from Chimerix (CMRX). On May 1, 2024, the Company released an updated corporate presentation for use in discussions with i...

Chimerix Releases Updated Corporate Presentation for Investors

Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chimerix (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmrx-stock-quote/">CMRX</a>) just reported results for the first quarter of 2024.<ul><li>Chimerix reported earnings per share of -25 cents. This was below the analyst estimate for EPS of -21 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cmrx-stock-earnings-chimerix-for-q1-of-2024/">CMRX Stock Earnings: Chimerix Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CMRX Stock Earnings: Chimerix Misses EPS for Q1 2024

Naureen Quibria, an analyst from Capital One Financial, reiterated the Buy rating on Chimerix (CMRX – Research Report). The associated price target...

Chimerix's Strong Financials and Promising ONC201 Developments Merit Buy Rating

Analyst Edward White from H.C. Wainwright reiterated a Buy rating on Chimerix (CMRX – Research Report) and keeping the price target at $11.00. Edwa...

Strong Buy Rating for Chimerix on Robust Financials and Promising Drug Pipeline

JonesTrading analyst Soumit Roy maintained a Buy rating on Chimerix (CMRX – Research Report) today and set a price target of $5.00. Soumit Roy has ...

Buy Rating Justified by Chimerix's Upcoming Catalysts and Strong Financials

ALKS

AMRN

AXTA

BIPC

BLCO

BRSP

CENX

CHEF

CNDT

COCO

DFIN

EEFT

ENTG

EXTR

FLEX

GNRC

GRMN

GTHX

IDXX

LIVN

MTRN

NBIX

NCLH

NHTC

PUMP

RGEN

ROCK

SHOO

SITE

SLGN

SMMT

STGW

TCPC

TECH

TRIN

TTMI

USAP

UTHR

Press Releases

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

Chimerix Appoints Lisa Decker to Board of Directors

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

Chimerix to Present at TD Cowen 44th Annual Health Care Conference

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

Chimerix Appoints Marc D. Kozin to Board of Directors

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Chimerix Stock (NASDAQ:CMRX), Short Interest Report

People Also Watch